Eisai Co., Ltd. EII.F Stock
Eisai Co., Ltd. Price Chart
Eisai Co., Ltd. EII.F Financial and Trading Overview
Eisai Co., Ltd. stock price | 39.93 EUR |
Previous Close | 61.62 EUR |
Open | 61.96 EUR |
Bid | 61.16 EUR x 10000 |
Ask | 63.6 EUR x 20000 |
Day's Range | 61.96 - 61.96 EUR |
52 Week Range | 35.47 - 73.2 EUR |
Volume | 1 EUR |
Avg. Volume | 36 EUR |
Market Cap | 18.1B EUR |
Beta (5Y Monthly) | 0.149425 |
PE Ratio (TTM) | 27.056768 |
EPS (TTM) | 0.87 EUR |
Forward Dividend & Yield | 1.08 (1.50%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | N/A |
EII.F Valuation Measures
Enterprise Value | -99789463552 EUR |
Trailing P/E | 27.056768 |
Forward P/E | 45.896294 |
PEG Ratio (5 yr expected) | 214038 |
Price/Sales (ttm) | 0.024319315 |
Price/Book (mrq) | 0.022221481 |
Enterprise Value/Revenue | -0.134 |
Enterprise Value/EBITDA | -1.22 |
Trading Information
Eisai Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.149425 |
52-Week Change | 85.17% |
S&P500 52-Week Change | 20.43% |
52 Week High | 73.2 EUR |
52 Week Low | 35.47 EUR |
50-Day Moving Average | 55.31 EUR |
200-Day Moving Average | 55.23 EUR |
EII.F Share Statistics
Avg. Volume (3 month) | 36 EUR |
Avg. Daily Volume (10-Days) | 147 EUR |
Shares Outstanding | 286.7M |
Float | 269.21M |
Short Ratio | N/A |
% Held by Insiders | 3.43% |
% Held by Institutions | 42.83% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 160 |
Trailing Annual Dividend Yield | 259.65% |
5 Year Average Dividend Yield | 214.00% |
Payout Ratio | 0.4271 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 7.44% |
Operating Margin (ttm) | 5.61% |
Gross Margin | 76.11% |
EBITDA Margin | 10.98% |
Management Effectiveness
Return on Assets (ttm) | 2.08% |
Return on Equity (ttm) | 7.13% |
Income Statement
Revenue (ttm) | 744.4B EUR |
Revenue Per Share (ttm) | 2595.93 EUR |
Quarterly Revenue Growth (yoy) | 3.79% |
Gross Profit (ttm) | N/A |
EBITDA | 81.79B EUR |
Net Income Avi to Common (ttm) | 55.43B EUR |
Diluted EPS (ttm) | 2.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 267.35B EUR |
Total Cash Per Share (mrq) | 931.86 EUR |
Total Debt (mrq) | 126.11B EUR |
Total Debt/Equity (mrq) | 15.33 EUR |
Current Ratio (mrq) | 2.081 |
Book Value Per Share (mrq) | 2788.293 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1772000000 EUR |
Levered Free Cash Flow (ttm) | -49332875264 EUR |
Profile of Eisai Co., Ltd.
Country | Germany |
State | N/A |
City | Tokyo |
Address | 4-6-10, Koishikawa |
ZIP | 112-8088 |
Phone | 81 3 3817 3700 |
Website | https://www.eisai.co.jp |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Q&A For Eisai Co., Ltd. Stock
What is a current EII.F stock price?
Eisai Co., Ltd. EII.F stock price today per share is 39.93 EUR.
How to purchase Eisai Co., Ltd. stock?
You can buy EII.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eisai Co., Ltd.?
The stock symbol or ticker of Eisai Co., Ltd. is EII.F.
Which industry does the Eisai Co., Ltd. company belong to?
The Eisai Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Eisai Co., Ltd. have in circulation?
The max supply of Eisai Co., Ltd. shares is 290.7M.
What is Eisai Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Eisai Co., Ltd. PE Ratio is 45.89655300 now.
What was Eisai Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Eisai Co., Ltd. EPS is 0.87 EUR over the trailing 12 months.
Which sector does the Eisai Co., Ltd. company belong to?
The Eisai Co., Ltd. sector is Healthcare.